Beta
285827

COMPARING SERUM PENTRAXIN 3 IN DIABETIC PATIENTS WITH AND WITHOUT RETINOPATHY.

Article

Last updated: 04 Jan 2025

Subjects

-

Tags

-

Abstract

Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Diabetic retinopathy is one of the most prominent pathologic vascular complications of diabetes and is the most common cause of blindness in the working-age group.
The most common cause of vision loss in diabetic retinopathy is diabetic macular edema.Diabetic retinopathy can be classified into two categories: non-proliferative and proliferative. Risk factors include duration of diabetes, poor glycemic control, hypertension, diabetic nephropathy and dyslipidemia.
Screening is important to early detect preventable blindness. In type 2 diabetes patients, first eye examination should be initiated once a diagnosis of diabetes is confirmed, for type 1 diabetes, the timing being extended to 5 years after the onset of diabetes.
Pentraxins are a superfamily of evolutionarily conserved molecules with multi-functional roles in innate immunity and inflammation, such as regulation of complement activation and opsonization of pathogens. Pentraxin 3, a member of the pentraxin superfamily, includes C‐reactive protein and serum amyloid P. Pentraxin 3 is produced in response to inflammatory stimuli within a variety of cell types and tissues, in particular within the vasculature.
Pentraxin 3, as a long pentraxin, is produced by peripheral tissues and reflects impaired vascular endothelial function. Pentraxin 3 is an acute-phase reactant with a cyclic multimericstructure. Pentraxin 3 may reflect local inflammatory status in tissues and may serve as a biomarker of inflammation.

DOI

10.21608/alexpo.2023.193808.1562

Keywords

Pentraxin 3, diabetic, retinopathy

Authors

First Name

Yehia

Last Name

Ghanim

MiddleName

Mostafa

Affiliation

Department of Internal Medicine (Diabetes, Metabolism and Lipidology Unit), Faculty of Medicine, Alexandria University.

Email

yehia.ghanim@gmail.com

City

-

Orcid

-

First Name

Noha

Last Name

Amin

MiddleName

-

Affiliation

Department of Internal Medicine, Faculty of Medicine, Alexandria University

Email

nohaamin8@gmail.com

City

-

Orcid

-

First Name

Mai

Last Name

Badrah

MiddleName

Hesham

Affiliation

Department of Internal Medicine Faculty of Medicine Alexandria University

Email

drmaibadrah@gmail.com

City

-

Orcid

-

First Name

salma

Last Name

imbaby

MiddleName

-

Affiliation

Department of clinical and chemical pathology Faculty of medicine, Alexandria university, Egypt.

Email

salmaimbaby@hotmail.com

City

alexandria

Orcid

-

First Name

Soad

Last Name

Mostafa

MiddleName

Zakaria Mohammed

Affiliation

Department of Internal Medicine (Diabetes, Metabolism and Lipidology Unit), Faculty of Medicine, Alexandria University.

Email

dr.soadzakaria@gmail.com

City

-

Orcid

-

Volume

5

Article Issue

1

Related Issue

38639

Issue Date

2023-01-01

Receive Date

2023-02-15

Publish Date

2023-01-01

Page Start

23

Page End

24

Online ISSN

2682-2636

Link

https://alexpos.journals.ekb.eg/article_285827.html

Detail API

https://alexpos.journals.ekb.eg/service?article_code=285827

Order

1

Type

Preliminary preprint short reports of original research

Type Code

1,426

Publication Type

Journal

Publication Title

ALEXMED ePosters

Publication Link

https://alexpos.journals.ekb.eg/

MainTitle

COMPARING SERUM PENTRAXIN 3 IN DIABETIC PATIENTS WITH AND WITHOUT RETINOPATHY.

Details

Type

Article

Created At

26 Dec 2024